Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Frontline Science: High fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cells.

Clements VK, Long T, Long R, Figley C, Smith DMC, Ostrand-Rosenberg S.

J Leukoc Biol. 2018 Mar;103(3):395-407. doi: 10.1002/JLB.4HI0517-210R. Epub 2018 Jan 3.

PMID:
29345342
2.

Differential Content of Proteins, mRNAs, and miRNAs Suggests that MDSC and Their Exosomes May Mediate Distinct Immune Suppressive Functions.

Geis-Asteggiante L, Belew AT, Clements VK, Edwards NJ, Ostrand-Rosenberg S, El-Sayed NM, Fenselau C.

J Proteome Res. 2018 Jan 5;17(1):486-498. doi: 10.1021/acs.jproteome.7b00646. Epub 2017 Nov 27.

3.

Ubiquitin Conjugation Probed by Inflammation in Myeloid-Derived Suppressor Cell Extracellular Vesicles.

Adams KR, Chauhan S, Patel DB, Clements VK, Wang Y, Jay SM, Edwards NJ, Ostrand-Rosenberg S, Fenselau C.

J Proteome Res. 2018 Jan 5;17(1):315-324. doi: 10.1021/acs.jproteome.7b00585. Epub 2017 Nov 10.

4.

CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice.

Horn LA, Ciavattone NG, Atkinson R, Woldergerima N, Wolf J, Clements VK, Sinha P, Poudel M, Ostrand-Rosenberg S.

Oncotarget. 2017 Aug 3;8(35):57964-57980. doi: 10.18632/oncotarget.19865. eCollection 2017 Aug 29.

5.

Frontline Science: Myeloid-derived suppressor cells (MDSCs) facilitate maternal-fetal tolerance in mice.

Ostrand-Rosenberg S, Sinha P, Figley C, Long R, Park D, Carter D, Clements VK.

J Leukoc Biol. 2017 May;101(5):1091-1101. doi: 10.1189/jlb.1HI1016-306RR. Epub 2016 Dec 22.

6.

Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes.

Ku AW, Muhitch JB, Powers CA, Diehl M, Kim M, Fisher DT, Sharda AP, Clements VK, O'Loughlin K, Minderman H, Messmer MN, Ma J, Skitzki JJ, Steeber DA, Walcheck B, Ostrand-Rosenberg S, Abrams SI, Evans SS.

Elife. 2016 Dec 8;5. pii: e17375. doi: 10.7554/eLife.17375.

7.

HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells.

Parker KH, Sinha P, Horn LA, Clements VK, Yang H, Li J, Tracey KJ, Ostrand-Rosenberg S.

Cancer Res. 2014 Oct 15;74(20):5723-33. doi: 10.1158/0008-5472.CAN-13-2347. Epub 2014 Aug 27.

8.

Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.

Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK.

Semin Cancer Biol. 2012 Aug;22(4):275-81. doi: 10.1016/j.semcancer.2012.01.011. Epub 2012 Feb 1. Review.

9.

Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL.

Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S.

Blood. 2011 May 19;117(20):5381-90. doi: 10.1182/blood-2010-11-321752. Epub 2011 Mar 30.

10.

Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.

Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S.

Cancer Res. 2010 Jan 1;70(1):68-77. doi: 10.1158/0008-5472.CAN-09-2587. Epub 2009 Dec 22.

11.

Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells.

Hanson EM, Clements VK, Sinha P, Ilkovitch D, Ostrand-Rosenberg S.

J Immunol. 2009 Jul 15;183(2):937-44. doi: 10.4049/jimmunol.0804253. Epub 2009 Jun 24.

12.

Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4.

Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S.

J Leukoc Biol. 2009 Jun;85(6):996-1004. doi: 10.1189/jlb.0708446. Epub 2009 Mar 4.

13.

Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.

Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S.

Cancer Res. 2007 Oct 15;67(20):10019-26.

14.

The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes.

Thompson JA, Srivastava MK, Bosch JJ, Clements VK, Ksander BR, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2008 Mar;57(3):389-98. Epub 2007 Aug 28.

15.

Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.

Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S.

J Immunol. 2007 Jul 15;179(2):977-83.

16.

Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.

Sinha P, Clements VK, Fulton AM, Ostrand-Rosenberg S.

Cancer Res. 2007 May 1;67(9):4507-13.

17.

Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression.

Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S.

J Immunol. 2006 Jan 1;176(1):284-90.

18.
19.

Tumor immunity: a balancing act between T cell activation, macrophage activation and tumor-induced immune suppression.

Sinha P, Clements VK, Miller S, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2005 Nov;54(11):1137-42. Epub 2005 May 5. Review.

PMID:
15877228
20.
21.

Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease.

Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S.

Cancer Res. 2004 Mar 15;64(6):2205-11.

22.

Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy.

Dissanayake SK, Thompson JA, Bosch JJ, Clements VK, Chen PW, Ksander BR, Ostrand-Rosenberg S.

Cancer Res. 2004 Mar 1;64(5):1867-74.

23.

Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent.

Ostrand-Rosenberg S, Clements VK, Terabe M, Park JM, Berzofsky JA, Dissanayake SK.

J Immunol. 2002 Nov 15;169(10):5796-804.

24.

Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma.

Ostrand-Rosenberg S, Grusby MJ, Clements VK.

J Immunol. 2000 Dec 1;165(11):6015-9.

25.
26.

Cell-based vaccines for the stimulation of immunity to metastatic cancers.

Ostrand-Rosenberg S, Pulaski BA, Clements VK, Qi L, Pipeling MR, Hanyok LA.

Immunol Rev. 1999 Aug;170:101-14. Review.

PMID:
10566145
27.

Immunotherapy of established tumor with MHC class II and B7.1 cell-based tumor vaccines.

Ostrand-Rosenberg S, Pulaski BA, Armstrong TD, Clements VK.

Adv Exp Med Biol. 1998;451:259-64. No abstract available.

PMID:
10026883
28.
29.

MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes.

Armstrong TD, Clements VK, Ostrand-Rosenberg S.

J Immunol. 1998 Jan 15;160(2):661-6.

30.

Single amino acid mutations in the murine MHC class II A beta cytoplasmic domain abrogate antigen presentation.

Laufer TM, Smiley ST, Ranger A, Clements VK, Ostrand-Rosenberg S, Glimcher LH.

J Immunol. 1997 Dec 15;159(12):5914-20.

PMID:
9550388
31.

Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.

Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S.

Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6886-91.

32.

Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.

Baskar S, Clements VK, Glimcher LH, Nabavi N, Ostrand-Rosenberg S.

J Immunol. 1996 May 15;156(10):3821-7.

PMID:
8621919
33.

Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.

Ostrand-Rosenberg S, Baskar S, Patterson N, Clements VK.

Tissue Antigens. 1996 May;47(5):414-21.

PMID:
8795142
34.

Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection.

Lamousé-Smith E, Clements VK, Ostrand-Rosenberg S.

J Immunol. 1993 Dec 1;151(11):6283-90.

PMID:
8245467
35.

Invariant chain alters the malignant phenotype of MHC class II+ tumor cells.

Clements VK, Baskar S, Armstrong TD, Ostrand-Rosenberg S.

J Immunol. 1992 Oct 1;149(7):2391-6.

PMID:
1527384
36.

Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule.

Ostrand-Rosenberg S, Roby CA, Clements VK.

J Immunol. 1991 Oct 1;147(7):2419-22.

PMID:
1918972
37.

Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejection.

Ostrand-Rosenberg S, Garcia EP, Roby CA, Clements VK.

Semin Cancer Biol. 1991 Oct;2(5):311-9. Review.

PMID:
1773047
38.
39.

Transfection and expression of syngeneic H-2 genes does not reduce malignancy of H-2 negative teratocarcinoma cells in the autologous host.

Ostrand-Rosenberg S, Cole GA, Nishimura MI, Clements VK.

Cell Immunol. 1990 Jun;128(1):152-64.

PMID:
2344619
40.

Transfection of major histocompatibility complex class I and class II genes causes tumour rejection.

Ostrand-Rosenberg S, Clements VK, Thakur A, Cole GA.

J Immunogenet. 1989 Aug-Oct;16(4-5):343-9.

PMID:
2639907
41.

Embryonal carcinoma cells express Qa and Tla class I genes of the major histocompatibility complex.

Ostrand-Rosenberg S, Nickerson DA, Clements VK, Garcia EP, Lamouse-Smith E, Hood L, Stroynowski I.

Proc Natl Acad Sci U S A. 1989 Jul;86(13):5084-8.

42.

Allogeneic H-2 antigen expression is insufficient for tumor rejection.

Cole GA, Cole GA, Clements VK, Garcia EP, Ostrand-Rosenberg S.

Proc Natl Acad Sci U S A. 1987 Dec;84(23):8613-7.

Supplemental Content

Loading ...
Support Center